Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regen BioPharma (RGBP) Other Non Operating Income (2017 - 2025)

Historic Other Non Operating Income for Regen BioPharma (RGBP) over the last 9 years, with Q3 2025 value amounting to -$299216.0.

  • Regen BioPharma's Other Non Operating Income fell 771242.82% to -$299216.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$675528.0, marking a year-over-year decrease of 1641253.97%. This contributed to the annual value of -$675528.0 for FY2025, which is 1641253.97% down from last year.
  • Regen BioPharma's Other Non Operating Income amounted to -$299216.0 in Q3 2025, which was down 771242.82% from -$89259.0 recorded in Q2 2025.
  • Regen BioPharma's 5-year Other Non Operating Income high stood at $66.9 million for Q2 2022, and its period low was -$66.6 million during Q1 2022.
  • Moreover, its 5-year median value for Other Non Operating Income was $35949.0 (2023), whereas its average is -$83128.7.
  • In the last 5 years, Regen BioPharma's Other Non Operating Income skyrocketed by 107373.06% in 2022 and then tumbled by 3409885.06% in 2025.
  • Quarter analysis of 5 years shows Regen BioPharma's Other Non Operating Income stood at $3.0 million in 2021, then decreased by 28.64% to $2.1 million in 2022, then plummeted by 98.3% to $35949.0 in 2023, then tumbled by 1257.24% to -$416016.0 in 2024, then increased by 28.08% to -$299216.0 in 2025.
  • Its Other Non Operating Income stands at -$299216.0 for Q3 2025, versus -$89259.0 for Q2 2025 and $128963.0 for Q1 2025.